CANF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Can Fite Biopharma Ltd (CANF) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks significant positive catalysts, has bearish technical indicators, and its financial performance shows no growth trends. Additionally, no proprietary trading signals or influential trading activity support a buy decision.
The MACD is positive and expanding, which is a slightly bullish signal. However, the RSI is neutral at 50.32, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 3.057, with resistance at 3.187 and support at 2.927. Overall, the technical indicators suggest a weak or neutral trend.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
The stock has shown consistent price declines in the regular market (-2.84%), pre-market (-3.15%), and post-market (-0.97%). Financial performance remains stagnant with no YoY growth in revenue, net income, or EPS.
In Q4 2023, revenue remained flat at $155,000 (0.00% YoY), net income was -$1,652,000 (0.00% YoY), and EPS was -5.97 (0.00% YoY). Gross margin is 100%, but the lack of growth in key financial metrics is concerning.
No data on analyst ratings or price target changes.
